Improved Overall Survival Trends of Men with Newly Diagnosed M1 Prostate Cancer: A SWOG Phase III Trial Experience (S8494, S8894 and S9346)
Abstract
Purpose:
Frequent prostate specific antigen testing for screening and monitoring prostate cancer has led to significant stage migration. We evaluated whether overall survival in hormone naïve patients with metastatic prostate cancer has improved during the era of prostate specific antigen use. We also assessed whether any patient subsets benefited differentially during this period.
Materials and Methods:
We compared overall survival in 3 sequential phase III trials of 3,096 men with hormone naïve, metastatic prostate cancer who received similar androgen deprivation therapy, including 2 trials performed before the prostate specific antigen era (S8494 and S8894) and the other done during this era (S9346). Overall survival was adjusted for patient and disease risk factors in the latter 2 trials. Subgroups were evaluated by interactions of risk factors with trial.
Results:
Median overall survival was 30 months in S8494, 33 months in S8894 and 49 months in S9346. Adjusting for risk factors, there was a 22% lower risk of death in S9346 than in S8894 (HR 0.78, 95% CI 0.70, 0.87, p <0.001). The improvement in overall survival was greater in black American men (test of interaction p = 0.008). In S8494 and S8894 median survival for black men was 27 months, and 34 and 35 months for nonblack men, respectively. This racial difference disappeared in S9346 with overall survival of 48 and 49 months in black and nonblack men, respectively.
Conclusions:
Adjusting for risk factors, overall survival was significantly improved in the post-prostate specific antigen era trial. However, it cannot be concluded that this was attributable only to prostate specific antigen monitoring. Black men now have overall survival comparable to that of white men. Current estimates of survival should be used to design new trials in this population.
References
- 1 : Studies on Prostate cancer: the effect of castration, of estrogen and of androgen injection on serum phosphatase in metastatic carcinoma of the prostate. Cancer Res1941; 1: 293. Google Scholar
- 2 : A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med1989; 321: 419. Google Scholar
- 3 : Orchiectomy versus goserelin plus flutamide in patients with metastatic prostate cancer (EORTC 30853): European Organization for Research and Treatment of Cancer-Genitourinary Group. Cancer1993; 72: 3863. Google Scholar
- 4 : Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med1998; 339: 1036. Google Scholar
- 5 : Multicenter randomized trial comparing Zoladex with Zoladex plus flutamide in the treatment of advanced prostate cancer. Survival update. International Prostate Cancer Study Group. Cancer1993; 72: 3878. Google Scholar
- 6 Phase III Randomized Study of Intermittent Versus Continuous Combined Androgen-Deprivation Therapy Comprising Bicalutamide and Goserelin in Patients With Metastatic Stage IV Prostate Cancer Responsive to Such Therapy. Bethesda: National Cancer Institute, National Institutes of Health http://www.cancer.gov/clinicaltrials/search/view?cdrid=64184&version=HealthProfessional&protocolsearchid=8981071. Accessed March 1, 2012. Google Scholar
- 7 : SEER Cancer Statistics Review, 1975–2007. Bethesda: National Cancer Institute, National Institutes of Health http://seer.cancer.gov/csr/1975_2007. based on November 2009 SEER data submission. Posted to the SEER web site 2010. Accessed May 31, 2012. Google Scholar
- 8 : The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol2004; 22: 2141. Google Scholar
- 9 : Impact of PSA screening on the incidence of advanced stage prostate cancer in the US: a surveillance modeling approach. Med Decis Making2008; 28: 323. Google Scholar
- 10 : Cancer statistics, 2010. CA Cancer J Clin2010; 60: 277. Google Scholar
- 11 : Mortality results from a randomized prostate-cancer screening trial: PLCO Project Team. N Engl J Med2009; 360: 1310. Google Scholar
- 12 : Screening and prostate-cancer mortality in a randomized European study: ERSPC Investigators. N Engl J Med2009; 360: 1320. Google Scholar
- 13 : Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol2003; 21: 1232. Google Scholar
- 14 : Prostate-specific antigen velocity and survival for patients with hormone refractory metastatic prostate carcinoma. Cancer2006; 106: 63. Google Scholar
- 15 : Surrogate end point for prostate cancer specific mortality in patients with nonmetastatic hormone refractory prostate cancer. J Urol2005; 173: 1572. Link, Google Scholar
- 16 : Association of African-American ethnic background with survival in men with metastatic prostate cancer. J Natl Cancer Inst2001; 93: 219. Google Scholar
- 17 Surveillance, Epidemiology and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence-SEER 17 Regs Research Data, Nov 2009 Sub (1992–2007) + Hurricane Katrina Impacted Louisiana Cases, Nov 2009 Sub (1973–2007 varying)-Linked to County Attributes- Total US, 1969–2007, National Cancer Institute, Division of Cancer Control and Population Sciences. Google Scholar
- 18 : Prostate cancer state shift has eliminated the gap in disease-free survival in black and white American men after radical prostatectomy. J Urol2002; 168: 479. Link, Google Scholar
- 19 Surveillance, Epidemiology and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence-SEER 13 Regs Research Data, Nov 2009 Sub (1992–2007) <Katrina/Rita Population Adjustment>-Linked to County Attributes-Total US, 1969–2007 Counties, National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Cancer Statistics Branch, released April 2010, based on the November 2009 submission. Google Scholar
